Drug intelligence / Profile preview

BR2251

Development stage: Phase 2
Lead developer: BioRay Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

BR2251 is an orally available small molecule inhibitor of the urate transporter 1 (URAT1) being developed by BioRay Pharmaceutical for the treatment of primary gout and hyperuricemia. URAT1, encoded by the SLC22A12 gene, is a key transporter located on the apical membrane of proximal renal tubule cells responsible for the reabsorption of filtered uric acid from the urine back into the blood. By inhibiting URAT1, BR2251 increases the renal excretion of uric acid, thereby reducing serum uric acid levels. The drug is currently being evaluated in Phase II clinical trials to determine its efficacy and safety compared to standard-of-care xanthine oxidase inhibitors like febuxostat.

Targets

URAT1 (Uric Acid Transporter 1)

Beyond the preview

Go deeper on BR2251.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR2251.

Explore the full profile